CYP2D6 phenotype and the metabolism of nicotine and cotinine

被引:23
|
作者
Benowitz, NL
Jacob, P
PerezStable, E
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA
[2] UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
nicotine; cotinine; metabolism; CYP2D6;
D O I
10.1097/00008571-199606000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
That CYP2D6 activity is an important determinant of nicotine metabolism and that people who have abnormal CYP2D6 genes are poor metabolizers of nicotine has been reported in the medical literature. The aim of this study was to assess the role of CYP2D6 in nicotine metabolism, Specifically, we compared the clearance of stable isotope-labelled nicotine and cotinine in 11 poor and 33 extensive metabolizers of dextromethorphan, a probe for CYP2D6 activity, The groups were matched by gender, age and ethnicity, Nicotine and cotinine kinetics were quite similar for cases and controls, These data suggest that CYP2D6 is nob a major isozyme for the metabolism of nicotine or cotinine.
引用
收藏
页码:239 / 242
页数:4
相关论文
共 50 条
  • [21] Relationship of CYP2D6 status and toremifene metabolism
    Kim, J.
    Dalton, J. T.
    Veverka, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] CYP2D6 is primarily responsible for the metabolism of clomiphene
    Ghobadi, Cyrus
    Gregory, Anne
    Crewe, H. Kim
    Rostami-Hodjegan, Amin
    Lennard, Martin S.
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 101 - 105
  • [23] Enantioselective metabolism of primaquine by human CYP2D6
    Pius S Fasinu
    Babu L Tekwani
    NP Dhammika Nanayakkara
    Bharathi Avula
    HMT Bandara Herath
    Yan-Hong Wang
    Vijender R Adelli
    Mahmoud A Elsohly
    Shabana I Khan
    Ikhlas A Khan
    Brandon S Pybus
    Sean R Marcsisin
    Gregory A Reichard
    James D McChesney
    Larry A Walker
    Malaria Journal, 13
  • [24] Enantioselective metabolism of primaquine by human CYP2D6
    Fasinu, Pius S.
    Tekwani, Babu L.
    Nanayakkara, N. P. Dhammika
    Avula, Bharathi
    Herath, H. M. T. Bandara
    Wang, Yan-Hong
    Adelli, Vijender R.
    Elsohly, Mahmoud A.
    Khan, Shabana I.
    Khan, Ikhlas A.
    Pybus, Brandon S.
    Marcsisin, Sean R.
    Reichard, Gregory A.
    McChesney, James D.
    Walker, Larry A.
    MALARIA JOURNAL, 2014, 13
  • [25] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [26] Olanzapine metabolism by CYP1A2/CYP2D6 and hyperglycaemia
    Iwahashi, K
    ACTA NEUROPSYCHIATRICA, 2004, 16 (04) : 229 - 230
  • [27] DEBRISOQUINE HYDROXYLATION (CYP2D6) PHENOTYPE ASSIGNMENT BY GENOTYPING
    DALY, AK
    ARMSTRONG, M
    MONKMAN, SC
    IDLE, ME
    IDLE, JR
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 110 - 110
  • [28] Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population
    Adedeji, Waheed Adeola
    Igbinoba, Sharon Iyobor
    Fakeye, Titilayo O.
    Oladosu, Ibrahim Adebayo
    Fehintola, Fatai Adewale
    Ma, Qing
    Morse, Gene D.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) : 1145 - 1152
  • [29] CYP2D6 phenotype-based dosing of eliglustat
    Turpault, Sandrine
    Meng, Zhaoling
    Wang, Shining
    von Moltke, Lisa
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S118 - S118
  • [30] CYP2D6 genotype and phenotype relationship in South Indians
    Naveen, A. T.
    Prasanna, T.
    Farzana, B. L.
    Rajan, S.
    Adithan, C.
    JOURNAL OF POSTGRADUATE MEDICINE, 2006, 52 (04) : 253 - 256